RBC Life Sciences, Inc.
Other OTCTotal Valuation
RBC Life Sciences, Inc. carries a market capitalization of 1,549.00, placing it among publicly traded companies globally. Its enterprise value stands at -107,647.20, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1,549.00 |
| Enterprise Value | -107,647.20 |
Share Statistics
RBC Life Sciences, Inc. currently has 2.21M shares outstanding.
| Shares Outstanding | 2.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.02, and the price-to-book ratio stands at -0.09.
| PE Ratio | N/A |
| PS Ratio | 0.02 |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | 1.48 |
| P/OCF Ratio | 2.08 |
Financial Position
RBC Life Sciences, Inc. maintains a current ratio of 1.75, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.75 |
| Quick Ratio | 0.37 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 12.18 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.40 |
Taxes
Over the trailing twelve months, RBC Life Sciences, Inc. has paid 94,210.00 in income taxes, reflecting an effective tax rate of 63.73.
| Income Tax | 94,210.00 |
| Effective Tax Rate | 63.73 |
Stock Price Statistics
RBC Life Sciences, Inc.'s stock has gained approximately 600.00002% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 600.00002% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, RBC Life Sciences, Inc. generated 26.03M in revenue and converted that into -233,225.00 in net income, yielding earnings per share of -0.11. EBITDA reached 212,681.00, while operating income came in at -139,015.00.
| Revenue | 26.03M |
| Gross Profit | 13.87M |
| Operating Income | -139,015.00 |
| Pretax Income | -139,015.00 |
| Net Income | -233,225.00 |
| EBITDA | 212,681.00 |
| EBIT | -139,015.00 |
| Earnings Per Share (EPS) | -0.11 |
Balance Sheet
Total book value stands at -6.98M, with working capital of 3.83M providing operational flexibility.
| Cash & Cash Equivalents | 727,290.00 |
| Total Debt | N/A |
| Net Debt | -727,290.00 |
| Equity (Book Value) | -6.98M |
| Book Value Per Share | -3.16 |
| Working Capital | 3.83M |
Cash Flow
RBC Life Sciences, Inc. produced 298,399.00 in operating cash flow over the past twelve months. After subtracting -120,875.00 in capital expenditures, free cash flow totaled 177,524.00 - equivalent to 0.08 per share.
| Operating Cash Flow | 298,399.00 |
| Capital Expenditures | -120,875.00 |
| Free Cash Flow | 177,524.00 |
| FCF Per Share | 0.08 |
Margins
RBC Life Sciences, Inc. operates with a gross margin of 53.28, reflecting its pricing power and cost economics. The operating margin of -0.53 and net profit margin of -0.90 provide insight into operational efficiency.
| Gross Margin | 53.28 |
| Operating Margin | -0.53 |
| Pretax Margin | -0.53 |
| Profit Margin | -0.90 |
| EBITDA Margin | 0.82 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | 67.66 |
Stock Splits
RBC Life Sciences, Inc.'s most recent stock split took place on August 12, 2013 with a 10:1 split ratio.
| Last Split Date | 8/12/2013 |
| Split Ratio | 10:1 |
Scores
RBC Life Sciences, Inc. posts an Altman Z-Score of 2.09, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.09 |